Bold reality check: Novo Nordisk argues its GLP-1 Alzheimer's trials were the right scientific move, even though the studies didn’t meet their primary goals. This stance comes as the company defends decisions to pursue two-year, multinational trials of the GLP-1 diabetes drug semaglutide (sold as Rybelsus) in roughly 4,000 Alzheimer's patients, despite criticism that the trial design had flaws.
Context matters. Novo announced in late November that the pivotal trials failed to show a statistically significant slowing of cognitive decline in participants treated with semaglutide versus placebo. Nonetheless, a top Novo executive framed the effort as a necessary step to answer a meaningful scientific question, not a wasted venture. Peter Johannsen, Novo’s international medical vice president, reiterated this view during a Clinical Trials in Alzheimer’s Disease meeting in San Diego.
Key evidence cited by Novo centers on consolidated data suggesting the GLP-1 hormone plays a role in neurotransmission and affects multiple brain pathways. However, Alzheimer’s disease remains defined by amyloid plaques, and Johannsen acknowledged the pathology is complex. He emphasized that the disease likely involves diverse genetic signatures and various interacting factors that complicate any single therapeutic approach.
Upcoming disclosures include initial results from the two 2-year trials, which compared Rybelsus against a placebo in nearly 4,000 participants. Full results are slated for presentation at another medical meeting in March. A brief press release last week stated the studies did not achieve their primary objectives.
Context on cognitive outcomes in diabetes patients using GLP-1 therapies has been mixed. Retrospective analyses have suggested cognitive benefits after about a year of GLP-1 treatment, with improvements potentially increasing over time. However, many of these analyses did not consistently specify dementia type or rely on precise biomarker confirmation for Alzheimer’s disease, relying instead on clinical diagnoses or broader cognitive assessments.
Estimates place the share of dementia cases due to Alzheimer’s at about 60%, with vascular and other etiologies accounting for the remainder, according to the Alzheimer’s Association. Johannsen also highlighted potential biases in real-world data: patients receiving GLP-1s typically have access to endocrinologists and may belong to higher socioeconomic groups, which can influence diagnosis timing, healthcare engagement, and overall outcomes. Additionally, those on GLP-1 therapies for diabetes often achieve better glycemic control, which in turn could impact disease trajectories or the likelihood of seeking further dementia evaluation.
In summary, Novo Nordisk remains committed to pursuing scientific answers about GLP-1 therapies and Alzheimer’s disease, even as the current trials did not meet their predefined goals. The company will continue to share results and context with the scientific community, inviting ongoing discussion about the potential role of GLP-1-based approaches in neurodegenerative disease.
Reporting by Deena Beasley; Editing by Bill Berkrot
Our Standards: The Thomson Reuters Trust Principles.
